Details of the Drug
General Information of Drug (ID: DMNV1P3)
Drug Name |
3-Hydroxy-benzamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; 3-Hydroxy-benzamide; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 137.14 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||